Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMelrose Regulatory News (MRO)

Share Price Information for Melrose (MRO)

Share Price is delayed by 15 minutes
Get Live Data
453.70    -5.90 (-1.28%)
Bid:
454.70
Ask:
454.90
Spread: 0.20 (0.044%)
Market Cap: £5.65b
MRO Live PriceLast checked at - London Stock Exchange

Intraday Melrose Share Chart

Disposal

6 Jun 2022 07:00

RNS Number : 6934N
Melrose Industries PLC
06 June 2022
 

3 June 2022

MELROSE INDUSTRIES PLC

 

SALE OF ERGOTRON

 

Sale of Ergotron

Melrose Industries PLC ("Melrose", the "Company" or the "Group") has entered into an agreement to sell its Ergotron business ("Ergotron"), to funds managed by The Sterling Group ("Sterling") for total consideration of approximately $650 million (c.£520 million), payable in cash on completion (the "Disposal"). Ergotron is a leading designer, manufacturer and distributor of ergonomic products for use in a variety of working, learning and healthcare environments, with gross assets (mostly goodwill) as at 31 December 2021 of £617 million and 2021 adjusted operating profit of £58 million (2021 EBITDA £62 million). 

Completion of the Disposal is expected to occur in the third quarter of 2022 ("Completion") and is conditional upon customary US antitrust approvals. On or before Completion, Melrose will announce how it intends to use the net proceeds from the Disposal. 

 

Successful execution of Melrose's strategy for Nortek

Having sold the Nortek Air Management and Nortek Control businesses last year, Ergotron is the last of the businesses remaining from the Nortek Inc acquisition in 2016. On Completion, Melrose will have more than doubled shareholders' initial investment, whilst transforming the Nortek businesses themselves.

Refocusing them away from unprofitable work, Melrose made the significant investment necessary to implement operational best practices, increase R&D, develop new products and build stronger customer relationships. These actions resulted in an almost doubling of adjusted operating margins and ensured each business remained highly cash generative, with over $1 billion generated during Melrose ownership.

This strong support and appropriate investment under Melrose ownership unlocked the potential of all the Nortek businesses and set them on the path for further success under new owners for the next stage of their development. 

 

Simon Peckham, Chief Executive of Melrose, today said:

"The sale of Ergotron is the final step in our Nortek ownership cycle, capping what has been a very successful acquisition for Melrose shareholders. We will have more than doubled shareholders' equity investment in Nortek and have transformed the businesses themselves. Our attention now remains firmly on achieving the same result for the current Group." 

 

Enquiries:

Investor Relations:

+44 (0) 7974 974690

ir@melroseplc.net

 

Montfort Communications - Financial PR:

+44 (0) 20 3514 0897

Nick Miles miles@montfort.london

+44 (0) 7739 701634

Charlotte McMullen mcmullen@montfort.london

+44 (0) 7921 881 800

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISBCGDLXXGDGDU
Date   Source Headline
22nd Jul 20207:00 amRNSTrading Statement
4th Jun 20202:36 pmRNSDirector/PDMR Shareholding
28th May 20207:00 amRNSDirector/PDMR Shareholding
14th May 20207:00 amRNSDirector/PDMR Shareholding
7th May 202012:56 pmRNSResult of AGM
7th May 20207:00 amRNSTrading Statement
6th May 20204:56 pmRNSHolding(s) in Company - Replacement
5th May 20204:10 pmRNSHolding(s) in Company
5th May 20204:09 pmRNSHolding(s) in Company
4th May 20207:00 amRNSHolding(s) in Company
1st May 20205:05 pmRNSHolding(s) in Company
28th Apr 20205:02 pmRNSRegulatory Filing – LR.9.2.6E
15th Apr 202011:03 amRNSHolding(s) in Company
14th Apr 20207:00 amRNSHolding(s) in Company
3rd Apr 202011:04 amRNSAnnual Report and Notice of AGM
31st Mar 20209:57 amRNSStandard annual confirmation of POUs
30th Mar 20204:25 pmRNSTrading Statement
19th Mar 20209:42 amRNSHolding(s) in Company
16th Mar 20207:00 amRNSDirector/PDMR Shareholding
13th Mar 20203:33 pmRNSHolding(s) in Company
10th Mar 20209:46 amRNSDirector/PDMR Shareholding
9th Mar 202011:13 amRNSDirector/PDMR Shareholding
9th Mar 20207:00 amRNSDirector/PDMR Shareholding
5th Mar 20207:00 amRNSFinal Results
19th Nov 20197:00 amRNSTrading Statement
18th Oct 20194:30 pmRNSDirector/PDMR Shareholding
1st Oct 20197:00 amRNSAppointment of Independent Non-Executive Director
5th Sep 20197:00 amRNSHalf-year Report
14th Jun 20194:00 pmRNSDirector/PDMR Shareholding
29th May 20194:04 pmRNSDirector/PDMR Shareholding
9th May 201912:49 pmRNSResult of AGM
9th May 20197:00 amRNSTrading Statement
5th Apr 201912:55 pmRNS2018 Annual Report and Notice of AGM
3rd Apr 20191:20 pmRNSCapital Markets Day
1st Apr 20195:43 pmRNSPost-Offer Undertakings Report
18th Mar 20194:41 pmRNSDirector/PDMR Shareholding
11th Mar 20195:01 pmRNSDirector/PDMR Shareholding
7th Mar 20197:00 amRNSFinal Results
6th Mar 20197:00 amRNSSundry Disposals
19th Dec 20187:00 amRNSDirector/PDMR Shareholding
13th Nov 20187:00 amRNSTrading Statement
19th Oct 20183:27 pmRNSAmended Holding(s) in Company
19th Oct 20181:46 pmRNSHolding(s) in Company
17th Oct 20184:47 pmRNSDirector/PDMR Shareholding
8th Oct 201810:30 amRNSAppointment
4th Oct 20184:19 pmRNSDirector/PDMR Shareholding
1st Oct 20187:00 amRNSAppointment of Director
6th Sep 20187:00 amRNSHalf-year Report
28th Aug 20183:55 pmRNSHolding(s) in Company
28th Aug 20182:22 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.